CY1109227T1 - Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων - Google Patents
Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγωνInfo
- Publication number
- CY1109227T1 CY1109227T1 CY20091100743T CY091100743T CY1109227T1 CY 1109227 T1 CY1109227 T1 CY 1109227T1 CY 20091100743 T CY20091100743 T CY 20091100743T CY 091100743 T CY091100743 T CY 091100743T CY 1109227 T1 CY1109227 T1 CY 1109227T1
- Authority
- CY
- Cyprus
- Prior art keywords
- thionyl
- methyl
- phosphatidylinositol
- thiazol
- inhibitors
- Prior art date
Links
- XSTQXTKOICQHDC-UHFFFAOYSA-N 4-methyl-5-phenyl-1,3-thiazol-2-amine Chemical class N1=C(N)SC(C=2C=CC=CC=2)=C1C XSTQXTKOICQHDC-UHFFFAOYSA-N 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- -1 Thionyl Methyl Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003905 phosphatidylinositols Chemical class 0.000 title 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Οι ενώσεις του τύπου (I) σε ελεύθερη μορφή ή με μορφή άλατος Ra, Rb, R2, R3, R4 και R5 που έχουν την έννοια όπως αυτή υποδηλώνεται στην προδιαγραφή, είναι χρήσιμες για την θεραπεία νόσων που διαμεσολαβούνται από την 3-κινάση της φωσφατιδυλινοσιτόλης, όπως φλεγμονώδεις ασθένειες των αεραγωγών. Οι φαρμακευτικές συνθέσεις οι οποίες περιέχουν τις ενώσεις και η μέθοδος διεργασιών για την παρασκευή των ενώσεων επίσης περιγράφονται.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0320197.7A GB0320197D0 (en) | 2003-08-28 | 2003-08-28 | Organic compounds |
| EP04764560A EP1689391B1 (en) | 2003-08-28 | 2004-08-27 | 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109227T1 true CY1109227T1 (el) | 2014-07-02 |
Family
ID=28686509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100743T CY1109227T1 (el) | 2003-08-28 | 2009-07-14 | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7902375B2 (el) |
| EP (1) | EP1689391B1 (el) |
| JP (1) | JP4574618B2 (el) |
| KR (1) | KR100774038B1 (el) |
| CN (1) | CN1838953B (el) |
| AR (1) | AR045510A1 (el) |
| AT (1) | ATE429225T1 (el) |
| AU (1) | AU2004268050B2 (el) |
| BR (1) | BRPI0413934A (el) |
| CA (1) | CA2533175A1 (el) |
| CY (1) | CY1109227T1 (el) |
| DE (1) | DE602004020793D1 (el) |
| DK (1) | DK1689391T3 (el) |
| EC (1) | ECSP066383A (el) |
| ES (1) | ES2323000T3 (el) |
| GB (1) | GB0320197D0 (el) |
| HR (1) | HRP20090340T1 (el) |
| IL (1) | IL173035A0 (el) |
| IS (1) | IS2690B (el) |
| MA (1) | MA28007A1 (el) |
| MX (1) | MXPA06002217A (el) |
| MY (1) | MY135050A (el) |
| NO (1) | NO20061406L (el) |
| NZ (1) | NZ545139A (el) |
| PE (1) | PE20050872A1 (el) |
| PL (1) | PL1689391T3 (el) |
| PT (1) | PT1689391E (el) |
| RU (1) | RU2382783C2 (el) |
| SI (1) | SI1689391T1 (el) |
| TN (1) | TNSN06064A1 (el) |
| TW (1) | TWI347941B (el) |
| WO (1) | WO2005021519A2 (el) |
| ZA (1) | ZA200600415B (el) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| WO2005118543A1 (ja) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | キナーゼ阻害薬およびその用途 |
| WO2006037468A1 (en) * | 2004-09-30 | 2006-04-13 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv reverse transcriptase inhibitors |
| AU2006251161B2 (en) * | 2005-05-24 | 2011-06-30 | Merck Serono Sa | Thiazole derivatives and use thereof |
| AU2006251159B2 (en) | 2005-05-24 | 2011-09-22 | Merck Serono Sa | Thiazole derivatives and use thereof |
| ZA200801822B (en) | 2005-08-26 | 2009-09-30 | Serono Lab | Pyrazine derivatives and use as p13k inhibitors |
| GB0525671D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| AU2007219509A1 (en) * | 2006-01-18 | 2007-09-07 | Siena Biotech S.P.A | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| GB0608823D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of P13 kinase |
| GB0608854D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | P13 kinase inhibitors |
| GB0610243D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| GB0612630D0 (en) * | 2006-06-26 | 2006-08-02 | Novartis Ag | Organic compounds |
| KR20090110950A (ko) | 2007-02-22 | 2009-10-23 | 메르크 세로노 에스. 에이. | (피라진 유도체) 퀴녹살린 화합물 및 이의 용도 |
| EP2166843A4 (en) | 2007-06-01 | 2010-08-11 | Univ Princeton | TREATMENT OF VIRUS INFECTIONS BY MODULATION OF HOST CELL METABOLISMS |
| JP2011506560A (ja) | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体 |
| JP2011506563A (ja) * | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | ビスチアゾール誘導体、その製造方法および医薬品としてのその使用 |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| CN101684106B (zh) * | 2008-09-22 | 2013-06-12 | 北京摩力克科技有限公司 | 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途 |
| CN102388041B (zh) | 2009-02-12 | 2014-12-24 | 默克雪兰诺有限公司 | 2-吗啉代-吡啶并[3,2-d]嘧啶 |
| TWI466884B (zh) * | 2009-04-30 | 2015-01-01 | Glaxo Group Ltd | 6-(1h-吲哚-4-基)-4-(5-{[4-(1-甲基乙基)-1-哌嗪基]甲基}-1,3-噁唑-2-基)-1h-吲唑、其醫藥組合物及作為激酶活性抑制劑之用途 |
| EP2440556A1 (en) * | 2009-06-10 | 2012-04-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
| EA201200087A1 (ru) | 2009-07-02 | 2012-07-30 | Новартис Аг | 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k |
| US8293753B2 (en) * | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| WO2011048936A1 (ja) | 2009-10-19 | 2011-04-28 | 大正製薬株式会社 | アミノチアゾール誘導体 |
| CA2778174C (en) | 2009-11-13 | 2018-02-20 | Merck Serono S.A. | Tricyclic pyrazol amine derivatives as pi3k inhibitors |
| CN102821767A (zh) | 2010-02-03 | 2012-12-12 | 西格诺药品有限公司 | Lkb1突变作为对tor激酶抑制剂的敏感性的预测生物标记的鉴定 |
| GB201018124D0 (en) * | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| EP2727920B1 (en) * | 2011-07-29 | 2016-11-02 | FUJIFILM Corporation | 1,5-naphthyridine derivative or salt thereof |
| US20130158023A1 (en) | 2011-08-03 | 2013-06-20 | Signal Pharmaceuticals, Llc | Identification of gene expression as a predictive biomarker for lkb1 status |
| US9309236B2 (en) | 2011-10-05 | 2016-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | PI-kinase inhibitors with broad spectrum anti-infective activity |
| US9926309B2 (en) | 2011-10-05 | 2018-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US9630966B2 (en) | 2013-04-17 | 2017-04-25 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CN105392499B (zh) | 2013-04-17 | 2018-07-24 | 西格诺药品有限公司 | 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法 |
| HK1221951A1 (zh) | 2013-04-17 | 2017-06-16 | 西格诺药品有限公司 | 有關1-乙基-7-(2-甲基-6-(1H-1，2，4-三唑-3-基)吡啶-3-基)-3，4-二氫吡嗪並[2，3-b]吡嗪-2(1H)-酮的藥物製劑、程序、固體形式和使用方法 |
| JP2016516818A (ja) | 2013-04-17 | 2016-06-09 | シグナル ファーマシューティカルズ，エルエルシー | 癌を治療するためのｔｏｒキナーゼ阻害剤及びｎ−（３−（５−フルオロ−２−（４−（２−メトキシエトキシ）フェニルアミノ）ピリミジン−４−イルアミノ）フェニル）アクリルアミドを含む組合せ療法 |
| UA115805C2 (uk) | 2013-04-17 | 2017-12-26 | Сігнал Фармасьютікалз, Елелсі | Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати |
| BR112015026297B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit |
| WO2014172426A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| JP6401250B2 (ja) | 2013-05-29 | 2018-10-10 | シグナル ファーマシューティカルズ，エルエルシー | ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法 |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| EP3273955A4 (en) * | 2015-03-23 | 2019-05-01 | The University of Melbourne | TREATMENT OF RESPIRATORY DISEASES |
| JP6845165B2 (ja) * | 2015-06-30 | 2021-03-17 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｅｇｆｒ阻害剤およびその使用方法 |
| ES3010661T3 (en) | 2016-02-26 | 2025-04-04 | Univ Leland Stanford Junior | Pi-kinase inhibitors with anti-infective activity |
| JOP20190052A1 (ar) * | 2016-09-22 | 2019-03-21 | Astrazeneca Ab | 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز |
| CN110996955A (zh) | 2017-06-22 | 2020-04-10 | 细胞基因公司 | 以乙型肝炎病毒感染为特征的肝细胞癌的治疗 |
| MX2022010944A (es) | 2020-03-03 | 2022-11-09 | Pic Therapeutics Inc | Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos. |
| EP4392421A1 (en) | 2021-08-25 | 2024-07-03 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| CN116874442A (zh) * | 2023-07-27 | 2023-10-13 | 武汉呈瑞生物医药科技有限公司 | 一种有机化合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1279531A3 (ru) * | 1983-02-14 | 1986-12-23 | Ниппон Сода Компани Лимитед (Фирма) | Способ получени производных тиазолинотриазина |
| EP0519449A1 (en) * | 1991-06-21 | 1992-12-23 | Boehringer Mannheim Italia S.P.A. | 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract |
| GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| EP1218376B1 (en) | 1999-09-10 | 2005-11-09 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| EP1294690A2 (en) * | 2000-06-21 | 2003-03-26 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| BR0112674A (pt) * | 2000-07-26 | 2003-12-30 | Bristol Myers Squibb Co | Inibidores n-[5-[[[5-alquil-2-oxazolil]metil] tio]-2tiazolil]carboxamida de quinases dependentes de ciclina |
| US7265134B2 (en) * | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| PE20030968A1 (es) | 2002-02-28 | 2004-01-12 | Novartis Ag | Derivados de 5-feniltiazol como inhibidores de cinasas |
-
2003
- 2003-08-28 GB GBGB0320197.7A patent/GB0320197D0/en not_active Ceased
-
2004
- 2004-08-26 AR ARP040103072A patent/AR045510A1/es not_active Application Discontinuation
- 2004-08-26 PE PE2004000820A patent/PE20050872A1/es not_active Application Discontinuation
- 2004-08-26 TW TW093125599A patent/TWI347941B/zh not_active IP Right Cessation
- 2004-08-27 NZ NZ545139A patent/NZ545139A/en not_active IP Right Cessation
- 2004-08-27 BR BRPI0413934-8A patent/BRPI0413934A/pt not_active IP Right Cessation
- 2004-08-27 SI SI200431138T patent/SI1689391T1/sl unknown
- 2004-08-27 PT PT04764560T patent/PT1689391E/pt unknown
- 2004-08-27 ES ES04764560T patent/ES2323000T3/es not_active Expired - Lifetime
- 2004-08-27 JP JP2006524337A patent/JP4574618B2/ja not_active Expired - Fee Related
- 2004-08-27 KR KR1020067004006A patent/KR100774038B1/ko not_active Expired - Fee Related
- 2004-08-27 WO PCT/EP2004/009586 patent/WO2005021519A2/en active Application Filing
- 2004-08-27 EP EP04764560A patent/EP1689391B1/en not_active Expired - Lifetime
- 2004-08-27 DE DE602004020793T patent/DE602004020793D1/de not_active Expired - Lifetime
- 2004-08-27 HR HR20090340T patent/HRP20090340T1/xx unknown
- 2004-08-27 MY MYPI20043510A patent/MY135050A/en unknown
- 2004-08-27 MX MXPA06002217A patent/MXPA06002217A/es active IP Right Grant
- 2004-08-27 AU AU2004268050A patent/AU2004268050B2/en not_active Ceased
- 2004-08-27 US US10/568,053 patent/US7902375B2/en not_active Expired - Fee Related
- 2004-08-27 PL PL04764560T patent/PL1689391T3/pl unknown
- 2004-08-27 DK DK04764560T patent/DK1689391T3/da active
- 2004-08-27 AT AT04764560T patent/ATE429225T1/de active
- 2004-08-27 CN CN2004800237755A patent/CN1838953B/zh not_active Expired - Fee Related
- 2004-08-27 CA CA002533175A patent/CA2533175A1/en not_active Abandoned
- 2004-08-27 RU RU2006109545/04A patent/RU2382783C2/ru not_active IP Right Cessation
-
2006
- 2006-01-09 IL IL173035A patent/IL173035A0/en unknown
- 2006-01-16 ZA ZA200600415A patent/ZA200600415B/en unknown
- 2006-02-17 EC EC2006006383A patent/ECSP066383A/es unknown
- 2006-02-27 MA MA28835A patent/MA28007A1/fr unknown
- 2006-02-27 TN TNP2006000064A patent/TNSN06064A1/en unknown
- 2006-03-24 IS IS8372A patent/IS2690B/is unknown
- 2006-03-28 NO NO20061406A patent/NO20061406L/no not_active Application Discontinuation
-
2009
- 2009-07-14 CY CY20091100743T patent/CY1109227T1/el unknown
-
2011
- 2011-02-03 US US13/020,247 patent/US20110124624A1/en not_active Abandoned
- 2011-02-03 US US13/020,211 patent/US20110124693A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
| CY1112084T1 (el) | Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3 | |
| CY1109677T1 (el) | Παραγωγα κινολινης και χρηση αυτων ως μυκοβακτηριακων αναστολεων | |
| CY1108894T1 (el) | Νεα παραγωγα βενζιμιδαζολης | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| CY1117217T1 (el) | Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης | |
| HUS1600021I1 (hu) | MEK inhibitorok és módszerek azok felhasználására | |
| CY1106383T1 (el) | Νεες διφαινζυλαζητιδινονες, η διαδικασια για την παραγωγη τους, τα φαρμακευτικα παρασκευασματα που πepιεχουν τις ενωσεις τους καθως και η χρηση τους για την αντιμετωπιση των διαταραχων μεταβολισμου λιπιδιων | |
| CY1107426T1 (el) | Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων | |
| ATE495155T1 (de) | Heterocyclische inhibitoren von mek | |
| ATE370139T1 (de) | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs | |
| CY1108754T1 (el) | Νεα παραγωγα θειοφαινογλυκοσιδης, μεθοδος για την παρασκευη τους, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους | |
| CY1106138T1 (el) | Δεαζαπουρινες και οι χρησεις τους | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| CY1108752T1 (el) | Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα | |
| CY1105621T1 (el) | Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους | |
| SE0300480D0 (sv) | Novel compounds | |
| CY1108529T1 (el) | Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν | |
| DE60226729D1 (de) | Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| CY1110332T1 (el) | Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους | |
| PT1041072E (pt) | Acidos dioxociclopentil hidroxamicos | |
| SE0302139D0 (sv) | Novel compounds | |
| SE0403171D0 (sv) | New compounds | |
| CY1109376T1 (el) | Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης | |
| NO20073839L (no) | Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette |